<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="mutate">
            <roleset id="Mutate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="physical location where mutation happen// exon, intron //&#x0A;" />
                    <role n="1" descr="mutated entity   // gene //&#x0A;" />
                    <role n="2" descr="changes at molecular level/* always use prepositional phrase */&#x0A;" />
                    <role n="3" descr="changes at phenotype level /* secondary predication */  &#x0A;" />
                </roles>
                <example src="EMBO" no="0">
                    <text>Groucho binding was, however, abolished by mutating a conserved phenylalanine of the eh1/GEH sequence to glutamic acid (Jimnez et al., 1999).</text>
                    <arg n="0">a conserved phenylalanine</arg>
                    <arg n="1">the eh1/GEH sequence</arg>
                    <arg n="2">glutamic acid</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>In contrast, mutating the C-terminal MAP kinase sites (T235 and T239) essentially leads to abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolished EGF-stimulated increase in phosphorylation and prevented EGF-induced mobility shift</arg>
                </example>
                <example src="EMBO" no="2">
                    <text>Phosphorylation of PDK1 was not altered by treating the cells with insulin-like growth factor-I and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EMBO" no="3">
                    <text>The DNA-binding mutant(Stat5aEE-AA) of Stat5a was generated by mutating amino acids EE(437 and 438) to AA.</text>
                    <arg n="1">amino acids EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                    <arg n="3">The DNA-binding mutant(Stat5aEE-AA) of Stat5a</arg>
                </example>
                <example src="EMBO" no="4">
                    <text>The template fragments were mutated by the sequence of SAP97 RAT, accession No.Q62696, using the program Swiss PDB Viewer (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="MEDLINE" no="1">
                    <text>RCA is comprised of two major steps: (i) identifying pairs of residue positions that mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an uncommonly high number of other residues.</text>
                    <arg n="1">pairs of residue positions</arg>
                </example>
                <example src="MEDLINE" no="2">
                    <text>The exon 5 mutated allele with the premature translation termination and resulted in severe deficiency of Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the premature translation termination</arg>
                    <arg n="3">severe deficiency of Hex A</arg>
                </example>
                <example src="MEDLINE" no="3">
                    <text>The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and nclf mutant mice encodes a novel predicted transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and nclf mutant mice</arg>
                    <arg n="3">a novel predicted transmembrane protein</arg>
                </example>
                <example src="MEDLINE" no="4">
                    <text>This epitope, which is HLA-A2 restricted, includes two amino acids that commonly mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="MEDLINE" no="5">
                    <text>To determine how activators interact with the complex and to examine the importance of these interactions, relative to other potential targeting mechanisms, for SWI/SNF function, we sought to identify and mutate the activator-interaction domains in the complex.</text>
                    <arg n="1">the activator-interaction domains in the complex</arg>
                </example>
                <example src="MEDLINE" no="6">
                    <text>Transient expression of the exon 8 mutated alpha-chain cDNA in COS-1 cells resulted in deficiency of enzymatic activity.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA in COS-1 cells</arg>
                    <arg n="3">deficiency of enzymatic activity</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
